Seifert Johanna, Heck Johannes, Eckermann Gabriel, Singer Monika, Bleich Stefan, Grohmann Renate, Toto Sermin
Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover.
Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Hannover.
Psychiatr Prax. 2021 Nov;48(8):399-403. doi: 10.1055/a-1531-4460. Epub 2021 Aug 3.
Vaccines against SARS-CoV-2 have been available in the European Union since December 2020. Persons suffering from mental illness have an increased risk of a severe or fatal course following an infection with SARS-CoV-2. Thus, the question arises to what extent interactions between the newly approved vaccines and psychotropic drugs may be expected. Data on the tolerability and efficacy of vaccines against SARS-CoV-2 under treatment with psychotropic drugs are not available to date - however, potential interactions can be derived from previous investigations on vaccines against other pathogens, such as a reduced immune response with lower clinical efficacy and an increase in drug plasma levels due to the indirect vaccine-mediated inhibition of metabolizing enzymes. On the other hand, depressed patients treated with antidepressant medication show a better immune response.
自2020年12月起,欧盟已有针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗。患有精神疾病的人感染SARS-CoV-2后出现重症或致命病程的风险增加。因此,新批准的疫苗与精神药物之间可能存在何种程度的相互作用成为一个问题。目前尚无关于在使用精神药物治疗期间接种SARS-CoV-2疫苗的耐受性和有效性的数据——然而,潜在的相互作用可以从先前针对其他病原体疫苗的研究中推导出来,例如免疫反应降低导致临床疗效降低,以及由于疫苗间接介导的代谢酶抑制作用导致药物血浆水平升高。另一方面,接受抗抑郁药物治疗的抑郁症患者表现出更好的免疫反应。